Literature DB >> 23788475

Determination of critical concentrations of moxifloxacin and gatifloxacin for drug susceptibility testing of Mycobacterium tuberculosis in the BACTEC MGIT 960 system.

Yu Isaeva1, A Bukatina, L Krylova, E Nosova, M Makarova, A Moroz.   

Abstract

OBJECTIVES: To determine critical concentrations of moxifloxacin and gatifloxacin for rapid evaluation of drug susceptibility of Mycobacterium tuberculosis in Middlebrook 7H9 broth using the automated system BACTEC™ MGIT™ 960.
METHODS: In total we studied 152 strains. Critical concentrations of moxifloxacin and gatifloxacin in the BACTEC™ MGIT™ 960 and on Lowenstein-Jensen medium were determined using a panel of 68 strains. The proportion method on Middlebrook 7H10 medium was used as a reference method. Drug susceptibility testing against fluoroquinolones was done for the other 84 strains using the established critical concentrations. The gyrA and gyrB genes of all strains were studied by molecular tests.
RESULTS: The critical concentrations determined for moxifloxacin and gatifloxacin were 0.25 mg/L in the BACTEC™ MGIT™ 960 system and 0.75 mg/L on Lowenstein-Jensen medium (absolute concentration method).
CONCLUSIONS: The moxifloxacin and gatifloxacin critical concentrations that we have established are reliable for rapid drug susceptibility testing in the BACTEC™ MGIT™ 960.

Entities:  

Keywords:  drug resistance; fluoroquinolones; microbiology; rapid tuberculosis diagnostics

Mesh:

Substances:

Year:  2013        PMID: 23788475     DOI: 10.1093/jac/dkt202

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  4 in total

1.  Concordance of Mycobacterium tuberculosis fluoroquinolone resistance testing: implications for treatment.

Authors:  M R Farhat; C D Mitnick; M F Franke; D Kaur; A Sloutsky; M Murray; K R Jacobson
Journal:  Int J Tuberc Lung Dis       Date:  2015-03       Impact factor: 2.373

2.  Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project.

Authors:  Matteo Zignol; Anna S Dean; Natavan Alikhanova; Sönke Andres; Andrea Maurizio Cabibbe; Daniela Maria Cirillo; Andrei Dadu; Andries Dreyer; Michèle Driesen; Christopher Gilpin; Rumina Hasan; Zahra Hasan; Sven Hoffner; Ashaque Husain; Alamdar Hussain; Nazir Ismail; Mostofa Kamal; Mikael Mansjö; Lindiwe Mvusi; Stefan Niemann; Shaheed V Omar; Ejaz Qadeer; Leen Rigouts; Sabine Ruesch-Gerdes; Marco Schito; Mehriban Seyfaddinova; Alena Skrahina; Sabira Tahseen; William A Wells; Ya Diul Mukadi; Michael Kimerling; Katherine Floyd; Karin Weyer; Mario C Raviglione
Journal:  Lancet Infect Dis       Date:  2016-07-07       Impact factor: 25.071

3.  Evaluation of TBMDR® and XDRA® for the detection of multidrug resistant and pre-extensively drug resistant tuberculosis.

Authors:  Eunjin Cho; Su Jin Lee; Jiyoung Lim; Dong Sik Kim; Namil Kim; Han Oh Park; Ji-Im Lee; Eunsoon Son; Sang Nae Cho; Wah Wah Aung; Jong Seok Lee
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2022-02-09

4.  Strong Increase in Moxifloxacin Resistance Rate among Multidrug-Resistant Mycobacterium tuberculosis Isolates in China, 2007 to 2013.

Authors:  Hui Xia; Yang Zheng; Dongxin Liu; Shengfen Wang; WenCong He; Bing Zhao; Yuanyuan Song; Xichao Ou; Yang Zhou; Susan van den Hof; Frank Cobelens; YanLin Zhao
Journal:  Microbiol Spectr       Date:  2021-12-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.